Summary
Long-term levodopa treatment in Parkinson's disease is typically associated with “motor side effects” consisting in dyskinesias and/or fluctuations in motility referred to as the on-off phenomena. The main objective of this prospective, randomized, multi-centre study was to determine to what extent the development of such complications could be prevented by partial substitution of levodopa monotherapy (L-DOPA/benserazide) by bromocriptine in patients with early symptoms of the disease. The basic trial population included 674 newly diagnosed Parkinsonian patients that were randomly allocated to monotherapy with levodopa or a combination therapy based upon a nearly 40% replacement of levodopa by bromocriptine. The two target regimens had to be consistently maintained for 42 months. Parkinsonian symptoms were assessed by means of the Webster rating scale, the Hoehn and Yahr scale, and the Zung Self-Rating Depression scale. Motor side effects and adverse events were recorded at each regular clinic visit.
Neurological symptoms improved and stabilized in a similar manner during treatment with both regimens throughout the study period. Motor side effects were observed in more patients on levodopa alone than on combination therapy (28.8 vs 20%; p=0.008). According to Kaplan-Meier estimates the cumulative probability of experiencing motor side effects was 0.43 on monotherapy, compared to 0.28 on combination therapy, which was equal to a one third reduction of risk (p=0.025). In regard to motor side effects, the degree of substitution of levodopa proved relevant: patients with >50% substitution by bromocriptine exhibited half the risk observed in those with <30% (p=0.045). The overall burden of motor side effects, as reflected by a sum score based upon the relevance, the severity and the extent of motor dysfunction, was also significantly less on combination therapy (p=0.046).
In conclusion, partial substitution of levodopa by bromocriptine (>30%) as first-line treatment of Parkinson's disease proves active in the prophylaxis of levodopa associated motor side effects. Early combination therapy therefore extends the period of optimal disease control.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armitage P, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell, Oxford, p 205
Bakheit AMO, Henderson LM, Moore AP, Simpson JA, Thomas M (1990) Long-term double masked trial of early treatment with L-Dopa plus bromocriptine versus L-Dopa alone in Parkinson's disease. Eur Neurol 30: 108–111
Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58: 293–299
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455
Boomsma F, Meerwaldt JD (1989) Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. J Neurol 236: 223–230
Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD (1990) Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 102: 21–27
Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329: 1021–1027
Cox DR (1972) Regression models and life-tables. J R Stat Soc [B] 34: 187–220
Eichstädt H (1993) unpublished results
Falk RH, DeSilva RA, Lown B (1981) Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist. Cardiovasc Res 15: 175–180
Fischer PA, Przuntek H, Majer M, Welzel D (1984) Kombinationsbehandlung früher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Ergebnisse einer multizentrischen Studie. Dtsch Med Wochenschr 109: 1279–1283
Gawel M, Riopelle R, Libman I (1986) Bromocriptine in the treatment of Parkinson's disease. A double-blind study against L-Dopa/carbidopa. Adv Neurol 45: 535–538
Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793–807
Gerlach M, Riederer P, Youdim MBH (1995) Neuroprotective therapeutic strategies: comparison of experimental and clinical results. Biochem Pharmacol 50: 1–16
Götz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37–122
Graham WC, Sambrook MA, Crossman AR (1993) Differential effect of chronic dopaminergic treatment on dopamine-D(1) and dopamine-D(2) receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 602: 290–303
Hely MA, Morris JGL, Rail D, Reid WGJ, O'Sullivan DJ, Williamson PM, Genge S, Broe G (1989) The Sydney multicentre study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 52: 324–328
Hoehn HM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442
Kao A, Kriett JM, Tobler HG, Detloff BL, Pritzker MR, Benson DW Jr, Benditt DG (1984) Bromocriptine treatment of digitalis-induced ventricular tachyarrhythmias: studies in a canine model. JACC 4: 1188–1194
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Lange KW, Rausch W-D, Gsell W, Naumann M, Oestreicher E, Riederer P (1994) Neuroprotection by dopamine agonists. J Neural Transm 43 [Suppl]: 183–201
LeWitt PA, Calne DB (1981) Recent advances in the treatment of Parkinson's disease: the role of bromocriptine. J Neural Transm 51: 175–184
Lieberman A, Goldstein M (1989) Dopamine agonists in advanced Parkinson's disease. In: Lieberman A, Lataste X (eds) Parkinson's disease. The role of dopamine agonists. The Parthenon Publishing Group, Carnforth, pp 35–53
Marsden CD, Parkes JD (1976) “On-off” effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet i: 292–296
Muenter MO, Sharpies NS, Tyce GM, Darley FL (1977) Patterns of dystonia (“I-D-I” and “D-I-D”) in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 52: 163–174
Nakanishi T, Mizuno Y, Goto I, Iwata M, Kanazawa I, Kowa H, Mannen T, Nishitani H, Ogawa N, Takahashi A, Tashiro K, Tohgi H, Yanagisawa N (1991) A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report. Eur Neurol 31 [Suppl 1]: 3–16
Nilsson A, Hökfelt B (1978) Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise and during insulin induced hypoglycemia. Acta Endoc 88 [Suppl 216]: 83–96
Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657: 207–213
Olanow CW (1993) A radical hypothesis for neurodegeneration. TINS 16: 439–444
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SU, Mantel N, McPherson K, Peto J, Smith PG (1976) Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I. Introduction and design. Br J Cancer 34: 585–612
Przuntek H, Welzel D, Blümner E, Danielczyk W, Letzel H, Kaiser H-J, Kraus PH, Riederer P, Schwarzmann D, Wolf H, Überla K (1992a) Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 43: 357–363
Przuntek H, Welzel D, Schwarzmann D, Letzel H, Kraus P (1992b) Primary combination therapy of early Parkinson's disease. Eur Neurol 32 [Suppl 1]: 36–45
Rinne UK (1985) Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 35: 1196–1198
Starke K, Majewski H, Ensinger H, Szabo B, Hedler L (1986) In vivo operation of prejunctional adrenoceptors in the peripheral sympathetic nervous system. In: Grobecker H, et al (eds) New aspects of the role of adrenoceptors in the cardiovascular system. Springer, Berlin Heidelberg New York Tokyo, pp 43–56
Tanaka M, Sotomatsu A, Yoshida T, Hirai S (1995) Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron. Neurosci Lett 183: 116–119
Van Loon GR, Sole MJ, Bain J, Ruse JL (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28: 425–434
Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Mod Treatment 5: 257–282
Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon C, Cornelius L, Ingenito A (1993) Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 43: 21–27
Wooten GF (1988) Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 24: 363–365
Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62: 1034–1038
Ziegler MG, Lake CR, Williams AC, Teychenne PF, Shoulson I, Steinsland O (1979) Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther 25: 137–142
Zung WW (1965) A self-rating depression scale. Arch Gen Psychiatry 12: 63–70
Author information
Authors and Affiliations
Additional information
Dedicated to Dr. H. Bühlmann on the occasion of his 80th birthday
Rights and permissions
About this article
Cite this article
Przuntek, H., Welzel, D., Gerlach, M. et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J. Neural Transmission 103, 699–715 (1996). https://doi.org/10.1007/BF01271230
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01271230